{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:18:49Z","timestamp":1788437929718,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":76,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Finnish Institute for Health and Welfare"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite extensive research on adherence in first-episode psychosis (FEP), reliance on self-report or clinician judgment has limited accuracy and obscured nuanced clinical associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This longitudinal study examined the predictive value of psychopathology, insight, and functioning for objectively measured treatment adherence across a one-year follow-up using therapeutic drug monitoring (TDM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seventy-eight FEP patients were assessed at baseline, 2 months, and 12 months. Clinical measures included the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms (SANS), Social and Occupational Functioning Assessment Scale (SOFAS), and the Schedule for the Assessment of Insight\u2013Expanded version (SAI-E). Adherence was defined by comparing plasma antipsychotic concentrations to prescribed doses according to international consensus guidelines. Generalized linear mixed models (GLMMs) were used to model time-dependent associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>While overall adherence declined, time alone was not a significant predictor. Instead, current positive symptom severity (approximately 4\u20135% lower odds of adherence per BPRS point) was associated with lower odds of adherence, while prior non-adherence predicted subsequent adherence. In contrast, insight, negative symptoms, and functioning showed no consistent association with adherence. A marginal association between improved functioning and better adherence was observed at 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adherence in FEP appears to fluctuate in relation to current clinical state rather than follow a stable linear pattern. These findings highlight the value of objective TDM monitoring and early intervention, supporting predictive models that incorporate evolving symptom patterns rather than static baseline measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinical trial number: not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-026-08301-9","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:15:24Z","timestamp":1781842524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of symptoms and illness insight on treatment adherence in first-episode psychosis: a one-year follow-up study using therapeutic drug monitoring"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1542-3746","authenticated-orcid":false,"given":"Juhani","family":"Leijala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Kampman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teemu","family":"Gunnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaana","family":"Suvisaari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"5","key":"8301_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5498\/wjp.v2.i5.74","volume":"2","author":"FJ Acosta","year":"2012","unstructured":"Acosta FJ, Hernandez JL, Pereira J, Herrera J, Rodriguez CJ. Medication adherence in schizophrenia. World J Psychiatry. 2012;2(5):74\u201382. https:\/\/doi.org\/10.5498\/wjp.v2.i5.74.","journal-title":"World J Psychiatry"},{"key":"8301_CR2","doi-asserted-by":"publisher","unstructured":"Revier CJ, Reininghaus U, Dutta R, Fearon P, Murray RM, Doody GA, et al. Ten-year outcomes of first-episode psychoses in the MRC \u00c6sOP-10 study. J Nerv Mental Disease. 2015;203(5). https:\/\/doi.org\/10.1097\/NMD.0000000000000295.","DOI":"10.1097\/NMD.0000000000000295"},{"issue":"4","key":"8301_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1176\/ajp.156.4.544","volume":"156","author":"DG Robinson","year":"1999","unstructured":"Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156(4):544\u20139. https:\/\/doi.org\/10.1176\/ajp.156.4.544.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"8301_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/2045125312474019","volume":"3","author":"K Higashi","year":"2013","unstructured":"Higashi K, Medic G, Littlewood KJ, Diez T, Granstrom O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200\u201318. https:\/\/doi.org\/10.1177\/2045125312474019.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"2\u20133","key":"8301_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","volume":"176","author":"D Novick","year":"2010","unstructured":"Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2\u20133):109\u201313. https:\/\/doi.org\/10.1016\/j.psychres.2009.05.004.","journal-title":"Psychiatry Res"},{"key":"8301_CR6","doi-asserted-by":"publisher","unstructured":"Yeisen RAH, Bjornestad J, Joa I, Johannessen JO, Opjordsmoen S. Experiences of antipsychotic use in patients with early psychosis: A two-year follow-up study. BMC Psychiatry. 2017;17(1). https:\/\/doi.org\/10.1186\/s12888-017-1425-9.","DOI":"10.1186\/s12888-017-1425-9"},{"issue":"10","key":"8301_CR7","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.v63n1007","volume":"63","author":"JP Lacro","year":"2002","unstructured":"Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892\u2013909.","journal-title":"J Clin Psychiatry"},{"key":"8301_CR8","doi-asserted-by":"publisher","unstructured":"Lepage M, Bodnar M, Buchy L, Joober R, Malla A. Early medication adherence and insight change in first-episode psychosis. Clin Schizophr Relat Psychoses. 2010;3(4). https:\/\/doi.org\/10.3371\/CSRP.3.4.2.","DOI":"10.3371\/CSRP.3.4.2"},{"issue":"1","key":"8301_CR9","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eurpsy.2010.06.003","volume":"27","author":"R Segarra","year":"2012","unstructured":"Segarra R, Ojeda N, Pena J, Garcia J, Rodriguez-Morales A, Ruiz I, et al. Longitudinal changes of insight in first episode psychosis and its relation to clinical symptoms, treatment adherence and global functioning: one-year follow-up from the Eiffel study. Eur Psychiatry. 2012;27(1):43\u20139. https:\/\/doi.org\/10.1016\/j.eurpsy.2010.06.003.","journal-title":"Eur Psychiatry"},{"issue":"6","key":"8301_CR10","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1093\/schbul\/sbm002","volume":"33","author":"TM Lincoln","year":"2007","unstructured":"Lincoln TM, Lullmann E, Rief W. Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophr Bull. 2007;33(6):1324\u201342. https:\/\/www.sbm002[pii].","journal-title":"Schizophr Bull"},{"issue":"4","key":"8301_CR11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1034\/j.1600-0447.2002.02437.x","volume":"106","author":"EL Coldham","year":"2002","unstructured":"Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002;106(4):286\u201390. https:\/\/www.2o437[pii].","journal-title":"Acta Psychiatr Scand"},{"key":"8301_CR12","doi-asserted-by":"publisher","unstructured":"Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. 2007;58(9). https:\/\/doi.org\/10.1176\/ps.2007.58.9.1187","DOI":"10.1176\/ps.2007.58.9.1187"},{"key":"8301_CR13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-116492","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018. https:\/\/doi.org\/10.1055\/s-0043-116492.","journal-title":"Pharmacopsychiatry"},{"key":"8301_CR14","doi-asserted-by":"publisher","unstructured":"Leijala J, Kampman O, Gunnar T, Suvisaari J. Treatment adherence in first-episode psychosis: A one-year follow-up study comparing self-reported adherence, pharmacy refill data, and therapeutic drug monitoring. Psychiatry Res. 2025;354. https:\/\/doi.org\/10.1016\/j.psychres.2025.116780.","DOI":"10.1016\/j.psychres.2025.116780"},{"key":"8301_CR15","doi-asserted-by":"publisher","unstructured":"Kein\u00e4nen J, Mantere O, Kiesepp\u00e4 T, M\u00e4ntyl\u00e4 T, Torniainen M, Lindgren M, et al. Early insulin resistance predicts weight gain and waist circumference increase in first-episode psychosis - A one year follow-up study. Schizophr Res. 2015;169(1\u20133). https:\/\/doi.org\/10.1016\/j.schres.2015.11.002.","DOI":"10.1016\/j.schres.2015.11.002"},{"key":"8301_CR16","doi-asserted-by":"publisher","unstructured":"M\u00e4ntyl\u00e4 T, Mantere O, Raij TT, Kiesepp\u00e4 T, Laitinen H, Leivisk\u00e4 J, et al. Altered activation of innate immunity associates with white matter volume and diffusion in first-episode psychosis. PLoS ONE. 2015;10(5). https:\/\/doi.org\/10.1371\/journal.pone.0125112.","DOI":"10.1371\/journal.pone.0125112"},{"key":"8301_CR17","volume-title":"Diagnostic and statistical manual of mental disorders","author":"APA","year":"2000","unstructured":"APA. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.","edition":"4"},{"key":"8301_CR18","first-page":"221","volume":"13","author":"J Ventura","year":"1993","unstructured":"Ventura J, Lukoff D, Nuechterlein K, Liberman RP, Green M, Shaner A. Brief Psychiatric Rating Scale Expanded version 4.0: Scales anchor points and administration manual. Int J Meth Psychiatr Res. 1993;13:221\u201344.","journal-title":"Int J Meth Psychiatr Res"},{"key":"8301_CR19","doi-asserted-by":"publisher","unstructured":"Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry. 1989;155(NOV. SUPPL. 7). https:\/\/doi.org\/10.1192\/s0007125000291496","DOI":"10.1192\/s0007125000291496"},{"key":"8301_CR20","first-page":"61","volume-title":"Treatment Compliance and the Therapeutic Alliance","author":"R Kemp","year":"1997","unstructured":"Kemp R, David A. Insight and compliance. In: Blackwell B, editor. Treatment Compliance and the Therapeutic Alliance. 1st ed. Amsterdam: Harwood Academic; 1997. pp. 61\u201384.","edition":"1"},{"key":"8301_CR21","unstructured":"WHO. ATC\/DDD Index 2024 [Internet]. 2024 [cited 2024 Apr 12]. Available from: https:\/\/atcddd.fhi.no\/atc_ddd_index_and_guidelines\/atc_ddd_index\/"},{"key":"8301_CR22","doi-asserted-by":"publisher","unstructured":"Leucht S, Samara M, Heres S, Davis JM. Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophr Bull. 2016;42. https:\/\/doi.org\/10.1093\/schbul\/sbv167.","DOI":"10.1093\/schbul\/sbv167"},{"key":"8301_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2016.07.001","author":"F Dazzi","year":"2016","unstructured":"Dazzi F, Shafer A, Lauriola M. Meta-analysis of the Brief Psychiatric Rating Scale \u2013 Expanded (BPRS-E) structure and arguments for a new version. J Psychiatr Res. 2016. https:\/\/doi.org\/10.1016\/j.jpsychires.2016.07.001.","journal-title":"J Psychiatr Res"},{"key":"8301_CR24","doi-asserted-by":"publisher","unstructured":"Bajraktarov S, Blazhevska Stoilkovska B, Russo M, Repi\u0161ti S, Maric NP, Dzubur Kulenovic A, et al. Factor structure of the brief psychiatric rating scale-expanded among outpatients with psychotic disorders in five Southeast European countries: evidence for five factors. Front Psychiatry. 2023;14. https:\/\/doi.org\/10.3389\/fpsyt.2023.1207577.","DOI":"10.3389\/fpsyt.2023.1207577"},{"key":"8301_CR25","unstructured":"Gunnar T, Ariniemi K. UHPLC-MS\/MS for targeted screening and simultaneous semiquantification\/quantification of over 150 drugs in whole blood. In: The 51st Annual Meeting of The International Association of Forensic Toxicologists (TIAFT). Madeira; 2013."},{"key":"8301_CR26","volume-title":"IBM SPSS Statistics for Windows, Version 29.0. Armonk","author":"IBM Corp","year":"2023","unstructured":"IBM Corp. IBM SPSS Statistics for Windows, Version 29.0. Armonk. NY, USA: IBM Corp; 2023."},{"key":"8301_CR27","volume-title":"RStudio: Integrated Development for R. Boston","author":"RStudio Team","year":"2022","unstructured":"RStudio Team. RStudio: Integrated Development for R. Boston. MA, USA: RStudio, PBC; 2022."},{"issue":"2","key":"8301_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1176\/appi.ps.61.2.189","volume":"61","author":"M Hill","year":"2010","unstructured":"Hill M, Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, et al. Nonadherence to medication four years after a first episode of psychosis and associated risk factors. Psychiatr Serv. 2010;61(2):189\u201392. https:\/\/doi.org\/10.1176\/appi.ps.61.2.189.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"8301_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/070674370905400106","volume":"54","author":"M Rabinovitch","year":"2009","unstructured":"Rabinovitch M, Bechard-Evans L, Schmitz N, Joober R, Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J psychiatryRevue canadienne de psychiatrie. 2009;54(1):28\u201335. https:\/\/doi.org\/10.1177\/070674370905400106.","journal-title":"Can J psychiatryRevue canadienne de psychiatrie"},{"key":"8301_CR30","doi-asserted-by":"publisher","unstructured":"Guitter M, Laprevote V, Lala A, Sturzu L, Dobre D, Schwan R. Rate and predictors of interrupted patient follow-up after first-episode psychosis - a retrospective cohort study in France. Early Interv Psychiatry. 2021;15(6). https:\/\/doi.org\/10.1111\/eip.13093.","DOI":"10.1111\/eip.13093"},{"issue":"9618","key":"8301_CR31","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(08)60486-9.","journal-title":"Lancet"},{"key":"8301_CR32","doi-asserted-by":"publisher","DOI":"10.1080\/09638237.2019.1581352","author":"J Bjornestad","year":"2020","unstructured":"Bjornestad J, Lavik KO, Davidson L, Hjeltnes A, Moltu C, Veseth M. Antipsychotic treatment\u2013a systematic literature review and meta-analysis of qualitative studies. J Mental Health. 2020. https:\/\/doi.org\/10.1080\/09638237.2019.1581352.","journal-title":"J Mental Health"},{"issue":"3","key":"8301_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1034\/j.1600-0447.2000.102003203.x","volume":"102","author":"H Verdoux","year":"2000","unstructured":"Verdoux H, Lengronne J, Liraud F, Gonzales B, Assens F, Abalan F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2000;102(3):203\u201310.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"8301_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.psychres.2011.10.015","volume":"196","author":"KA Steger","year":"2012","unstructured":"Steger KA, Cassidy C, Rabinovitch M, Joober R, Malla A. Impact of symptom resolution on medication adherence in first episode psychosis. Psychiatry Res. 2012;196(1):45\u201351. https:\/\/doi.org\/10.1016\/j.psychres.2011.10.015.","journal-title":"Psychiatry Res"},{"issue":"2\u20133","key":"8301_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0920-9964(01)00312-7","volume":"57","author":"DG Robinson","year":"2002","unstructured":"Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res. 2002;57(2\u20133):209\u201319. https:\/\/doi.org\/S0920996401003127[pii].","journal-title":"Schizophr Res"},{"key":"8301_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12888-015-0560-4","volume":"15","author":"D Novick","year":"2015","unstructured":"Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. BMC Psychiatry. 2015;15:184\u20139. https:\/\/doi.org\/10.1186\/s12888-015-0560-4.","journal-title":"BMC Psychiatry"},{"key":"8301_CR37","doi-asserted-by":"publisher","unstructured":"Homman LE, Smart SE, O\u2019Neill F, MacCabe JH. Attrition in longitudinal studies among patients with schizophrenia and other psychoses; findings from the STRATA collaboration. Psychiatry Res. 2021;305. https:\/\/doi.org\/10.1016\/j.psychres.2021.114211.","DOI":"10.1016\/j.psychres.2021.114211"},{"key":"8301_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgac012","author":"E Robson","year":"2022","unstructured":"Robson E, Greenwood K. Rates and predictors of disengagement and strength of engagement for people with a first episode of psychosis using early intervention services: a systematic review of predictors and meta-analysis of disengagement rates. Schizophrenia Bull Open. 2022. https:\/\/doi.org\/10.1093\/schizbullopen\/sgac012.","journal-title":"Schizophrenia Bull Open"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08301-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08301-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08301-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:02:53Z","timestamp":1788436973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08301-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8301"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08301-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the Ethics Committee of the Helsinki and Uusimaa Hospital District (257\/12\/03\/03\/2009), as well as from the institutional review boards of the Finnish Institute for Health and Welfare (THL) and the University of Helsinki. Written informed consent was obtained from all participants prior to inclusion in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"690"}}